CSLCMXHF 73 Market Cap is $37,877 Mil as of Jul. 01, 2026. GuruFocus rates CMXHF with a GF Score™ of 73/100 and a GF Value™ of $204.68 (Significantly Undervalued). The stock has 7 warning signs investors should review. Among 1,427 Biotechnology companies, CSL ranks better than 99.44% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). CSL's share price for the quarter that ended in Dec. 2025 was $115.5. CSL's Shares Outstanding (EOP) for the quarter that ended in Dec. 2025 was 482 Mil. Therefore, CSL's market cap for the quarter that ended in Dec. 2025 was $55,686 Mil.
CSL's quarterly market cap
declined
from Jun. 2024 ($91,721 Mil) to Jun. 2025 ($78,962 Mil) and
declined
from Jun. 2025 ($78,962 Mil) to Dec. 2025 ($55,686 Mil).
CSL's annual market cap
increased
from Jun. 2023 ($90,345 Mil) to Jun. 2024 ($91,721 Mil) but then
declined
from Jun. 2024 ($91,721 Mil) to Jun. 2025 ($78,962 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. CSL's Enterprise Value for Today is $49,996 Mil.
CSL (OTCPK:CMXHF) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
CSL Market Cap Related Terms
CSL Market Cap Historical Data
* Premium members only.
The historical data trend for CSL's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, CSL's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CSL Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CSL's Market Cap distribution charts can be found below:
* The bar in red indicates where CSL's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
CSL's Market Cap for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CSL (CMXHF) has a Market Cap of $37,877 Mil as of Jul. 01, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on CSL and its competitors. According to the industry distribution chart, CSL ranks #8 out of 1427 companies in the Biotechnology industry, placing it in the top 0.59999999999999%.
Is CSL's Market Cap too high?
CSL's current Market Cap is $37,877 Mil. The Biotechnology industry median Market Cap is 119.57. CSL's value of $37,877 Mil is 31577.7% above this industry median. Based on the distribution chart, CSL ranks #8 out of 1427 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, CSL has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CSL's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CSL ranks #8 out of 1427 companies for Market Cap. This places CSL in the top 1% of its industry — outperforming the majority of peers. The industry median Market Cap is 119.57. CSL's value of $37,877 Mil is 31577.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 119.57, based on 1,427 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CSL's current Market Cap of $37,877 Mil is 31577.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on CSL and its competitors. For the Biotechnology industry, the median Market Cap is 119.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CSL's current Market Cap is $37,877 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CSL stock overvalued right now?
Based on GuruFocus' analysis, CSL (CMXHF) is currently considered Significantly Undervalued. The stock's GF Value™ is $204.68, compared to a current price of $80.14 — trading 60.8% below its estimated fair value. The current Market Cap is $37,877 Mil and 31577.7% above the Biotechnology industry median of 119.57. CSL's overall GF Score™ is 73/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For CSL (CMXHF), the current Market Cap is $37,877 Mil as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CSL (CMXHF) Overvalued in 2026?
Based on GuruFocus' analysis, CSL stock appears to be undervalued.
The current stock price of $80.14 is trading 60.8% below its estimated GF Value™ of $204.68.
GuruFocus considers CSL to be Significantly Undervalued.
Key valuation signals for CMXHF:
Market Cap: $37,877 Mil
GF Value™: $204.68 vs. price of $80.14 (60.8% below fair value)
Industry Position: 31577.7% above the Biotechnology median (#8 of 1427)
No single metric tells the full story. See the CMXHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CSL is one of the largest global biotech companies and has three main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders, and neurological indications. CSL Seqirus is the world's second-largest influenza vaccination business and was acquired in fiscal 2016. CSL Vifor is an iron deficiency and nephrology business and was acquired in fiscal 2023. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.
73GF Score
Get the complete analysis for CMXHF
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CMXHF has been successfully added to your 
